Arash Rezazadeh Kalebasty Discusses Darolutamide Combination Safety in the ARASENS Study
March 31st 2023Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.
Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection
November 25th 2022Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.
Stephanie Jackson Discusses the Feasibility of a Discharge Lounge for Stem Cell Transplant Units
May 24th 2022Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses how collaboration between an oncology unit and discharge lounge can improve discharge times for patients who have undergone stem cell transplantation.